Creatine monohydrate in myotonic dystrophy: a double-blind, placebo-controlled clinical study.
We assessed safety and efficacy of creatine monohydrate (Cr) in myotonic dystrophy (DM1) in a double-blind, cross-over trial. Thirty-four patients with defined DM1 were randomized to receive Cr and placebo for eight weeks (10.6 g day 1-10, 5.3 g day 11-56) in one of 2 treatment sequences. There was no significant improvement using manual and quantitative muscle strength, daily-life activities, and patients' own global assessment comparing verum with placebo administration. Cr supplementation was well tolerated without clinically relevant side effects, but did not result in significant improvement of muscle strength or daily-life activities.
Walter
Maggie C
MC
Friedrich-Baur-Institute, Department of Neurology, Ludwig-Maximilians-University, Ziemssenstr. 1a, 80336 Munich, Germany. Maggie.Walter@lrz.uni-muenchen.de
Reilich
Peter
P
Lochmüller
Hanns
H
Kohnen
Ralph
R
Schlotter
Beate
B
Hautmann
Hubert
H
Dunkl
Elmar
E
Pongratz
Dieter
D
Müller-Felber
Wolfgang
W
D000203:Activities of Daily Living / Q000523:psychology; D000328:Adult; D003401:Creatine / Q000627:therapeutic use*; D018592:Cross-Over Studies; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018908:Muscle Weakness / Q000188:drug therapy / Q000503:physiopathology / Q000523:psychology; D009223:Myotonic Dystrophy / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D018709:Statistics, Nonparametric
D003401:Creatine